ArticleCureus2025
Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dapagliflozin attenuates hepatic steatosis and induces a fasting-mimicking metabolic state in C57BL/6 mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes (T2D) represents one of the most common metabolic disorders globally. Insulin resistance is a fundamental issue associated with the disorder, wherein cells in the adipose tissue, liver, and muscle resist the action of insulin, leading to dysregulation of glucose metabolism. T2D is a known, significant, and independent risk factor for the development and progression of dyslipidemia, a condition characterized by abnormal lipid levels in the blood. Inadequately controlled T2D can lead to dyslipidemia through various mechanisms. Dyslipidemia, i.e., alteration in the levels of plasma lipids typically characterized by increased levels of triglycerides (TGs), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C), is a significant and modifiable risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Materials and methods In this prospective, observational, parallel-group, open-label study, 383 patients of inadequately controlled T2D receiving metformin (500-2000 mg) were randomized to receive vildagliptin (group A) or dapagliflozin (group B) for a 24-week duration. We compared the effects of vildagliptin and dapagliflozin on hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and lipid profile at baseline and after 24 weeks of therapy. Results A total of 248 patients with T2D completed the follow-up for 24 weeks (mean age: 53.8±8.4 years, and the mean body mass index {BMI} was 25.0±3.4 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.